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Abstract
Carnitine palmitoyltransferase II (CPT II) deficiency is one of the most common causes of
fatty acid oxidation metabolism disorders. However, the molecular mechanism between
CPT2 gene polymorphisms and metabolic stress has not been fully clarified. We previously
reported that a number of patients show a thermal instable phenotype of compound hetero/
homozygous variants of CPT II. To understand the mechanism of the metabolic disorder re-
sulting from CPT II deficiency, the present study investigated CPT II variants in patient fibro-
blasts, [c.1102 G>A (p.V368I)] (heterozygous), [c.1102 G>A (p.V368I)] (homozygous), and
[c.1055 T>G (p.F352C)] (heterozygous) + [c.1102 G>A (p.V368I)] (homozygous) com-
pared with fibroblasts from healthy controls. CPT II variants exerted an effect of dominant
negative on the homotetrameric proteins that showed thermal instability, reduced residual
enzyme activities and a short half-life. Moreover, CPT II variant fibroblasts showed a signifi-
cant decrease in fatty acid β-oxidation and adenosine triphosphate generation, combined
with a reduced mitochondrial membrane potential, resulting in cellular apoptosis. Collective-
ly, our data indicate that the CPT II deficiency induces an energy crisis of the fatty acid met-
abolic pathway. These findings may contribute to the elucidation of the genetic factors
involved in metabolic disorder encephalopathy caused by the CPT II deficiency.
Introduction
The carnitine palmitoyl-transferase (CPT) system is component of adenosine triphosphate
(ATP) production through fatty acid β-oxidation [1–7]. It consists of two enzymes CPT I and
CPT II which located in the mitochondrial membranes. The CPT system transfers long chain
fatty acids from cytosol to mitochondrial. The rate-limiting step in the transfer of long chain
fatty acid is that CPT I transesterificates acyl-CoA to acylcarnitine [8, 9], but CPT II changes
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acylcarnitine to acyl-CoA. The CPT II protein is a homotetramer encoded by CPT2 gene which
located on chromosome 1p32, contains five exons ranging from 81 to 1,305 bp in size. Fatty
acid metabolized by β-oxidation pathway represents energy source performed particular in
muscle and also in nerve system. The autonomic recessive CPT II deficiency is the inherited
disease of the mitochondrial long chain fatty acid oxidation, includes a severe infantile hepato-
cardiomuscular form, a lethal neonatal form, and a myopathic form [10–14].
To date, more than 70 different mutations of CPT2 have recently been reported, and studies
have demonstrated the relationships between the CPT II deficiency genotypes and their clinical
phenotypes characterized by febrile convulsions and multiple-organ failure during high fever
[15–21]. However, the molecular mechanism underlying the relationship between CPT2 poly-
morphisms and metabolic stress has not been completely clarified. Previously, we have re-
ported that a number of influenza-associated encephalopathy patients exhibit a thermolabile
phenotype of compound hetero/homozygous variants of CPT II [20–22], and analyzed the en-
zymatic properties of CPT II variants expressed in transfected COS-7 cells. The direct bio-
chemical consequences of the mutations are still controversial. To understand the mechanisms
of the metabolic disorder resulting from CPT II deficiency, we studied CPT II variants in pa-
tient fibroblasts, [c.1102 G>A (p.V368I)] (heterozygous), [c.1102 G>A (p.V368I)] (homozy-
gous), and [c.1055 T>G (p.F352C)] (heterozygous) + [c.1102 G>A (p.V368I)] (homozygous)
compared with control fibroblasts. Our study hypothesis was that the CPT II deficiency caused
a lack of enzymatically active CPT II protein and induced an energy crisis in the fatty acid met-
abolic pathway. Our findings may contribute to the elucidation of the genetic factors involved
in metabolic disorder encephalopathy.
Materials and Methods
Materials
[1-14C] oleic acid, L-[methyl-3H] carnitine, L-[35S] methionine, and enhanced chemilumines-
cence detection reagents were bought from Amersham Pharmacia Biotech (Piscataway, NJ,
USA), the BCA reagent was from Pierce (Rockford, IL, USA). The ABI DyeDeoxy Terminator
Cycle Sequencing Kit was obtained from PE-Applied Biosystems (Foster City, CA, USA).
CPT II deficiency patients and CPT2 polymorphism analysis
This study was approved by the Ethics Review Committee for human genome analysis of the
Key Laboratory of Neuroregeneration, Nantong University. Informed written consents were
obtained from the adult patients and from the next of kin, caretakers, or guardians on behalf of
the minor patients in this study. To diagnose CPT II deficiency, patient plasma was examined
to determine the accumulation of long-chain acylcarnitines, which is indicative of disease. A
total of 12 patients were diagnosed with CPT II deficiency on the basis of clinical manifesta-
tions, including the abrupt onset of seizures and coma developing within 12–48 h after the
onset of high fever (40°C). In all patients, the age range was from 1 to 56 years, eight patients
were males and four were females. To confirm the diagnosis, CPT2mutation analysis was per-
formed by PCR-amplifying the five coding exons and flanking intronic regions of CPT2 from
genomic DNA extracted from EDTA—whole blood. The primers were intronic (S1 Table), and
have been described previously [20–23]. PCR products were sequenced directly by using ABI-
PRISM 3100 Genetic Analyzer. The PCR products were sequenced in both strands and the
analysis were performed in triplicate. The sequencing results showed the following mutations:
NM_000098.2 (CPT2_v001): [c.1102 G>A (p.V368I)] (heterozygous), and [c.1102 G>A
(p.V368I)] (homozygous), [c.1055 T>G (p.F352C)] (heterozygous) + [c.1102 G>A (p.V368I)]
(homozygous).
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Assay of CPT II activity and kinetic properties
We collected the fibroblasts of CPT II variations with clinical symptoms and biochemical mark-
ers characteristic of this inherited metabolic disorder. The control fibroblasts were bought from
company. These fibroblasts were cultured at 37°C in 5% CO2 in Dulbecco’s modified Eagle’s me-
dium (DMEM) containing 10% fetal serum (Indianapolis, IN, USA). CPT II activities in the fi-
broblast lysates were measured at 30°C for 2 h, by detection of palmitoyl-L-[methyl-3H]
carnitine formed from L-[methyl-3H] carnitine and palmitoyl-CoA [6]. The palmitoyl-L-
[methyl-3H] carnitine formed was extracted and radioactivity levels were counted. The Vmax and
Km values were analyzed by measuring the enzyme activity at 30°C by varying the L-[methyl-
3H]
carnitine concentrations. To analyze the heat stability of control and CPT II deficiency fibro-
blasts, cell lysates were pre-incubated at conditions simulating a high fever (41°C) or stable
conditions (30°C) for 0–2 h, and the enzyme activities were assayed after the addition of 200 μM
L-[methyl-3H] carnitine then continue incubated at 30°C for 2 h [20–23]. The protein concentra-
tions in the fibroblast lysates were assayed using the bicinchoninic acid protein assay reagent kit.
Expression of control and patient CPT2mRNA
To analyze CPT2mRNA expression levels of control and patient fibroblasts, total RNA was ex-
tracted using the RNeasy Mini Kit. The fibroblasts cDNA were synthesized using a random
primer and reverse transcriptase. The expression of CPT2mRNA levels was analyzed by real-
time quantitative PCR with CPT2-specific primers.
CPT II protein expression of control and patient fibroblasts was analyzed by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions, fol-
lowed by Western Blotting with anti-CPT II antibodies. The amount of CPT II total RNA and
proteins were expressed relative to those of β-actin control.
Mitochondrial membrane potential analysis
Fibroblasts were cultured for 5 h at 37°C or 41°C and then continue incubated for an another
15 min with 5,50, 6,60-Tetrachloro-1,10,3,30-tetraethylbenzimidazolyl-carbocyanineiodide fluo-
rescent dye (JC-1) from the Probes in the dark. Then they were washed with assay buffer and
immediately imaged with the red fluorescence channel (λexcitation: 560 ± 40 nm band pass filter,
λdetection: 630 ± 60 nm band pass filter) using a fluorescence microscope and with the green
fluorescence channel (λexcitation: 470 ± 40 nm band pass filter, λdetection: 535 ± 50 nm band pass
filter) [20, 21].
Apoptosis analysis of CPT II variants
The percentage of apoptotic control and patient fibroblasts was measured by flow cytometry.
Annexin V—FITC was added to cell suspensions following propidium iodide labelling, and the
number of apoptotic fibroblasts was counted by FACScan flow cytometry according to the
manufacturer’s protocol and based on an annexin V flow cytometry histogram. Fibroblasts in-
cubated with dimethyl sulfoxide (DMSO) were used as a control. Control and patient fibro-
blasts were also analyzed by a lactate dehydrogenase (LDH) cytotoxicity assay. The LDH
reagent and catalyst was added to the supernatant from fibroblast medium and incubated for
30 min at room temperature. The absorbance was recorded at 490 nm with background sub-
traction at 630 nm using the Synergy HT multi-detection Micro Plate Reader, and results were
shown as a percentage of LDH release. To analyze the apoptotic factor release, fibroblasts were
lysed and immunoblotted separately with anti-caspase-3,-caspase-8,-cytochrome c, and-Bid
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antibodies. CPT II protein expression levels were expressed relative to those of β-actin. All ex-
periments were carried out in triplicate.
CPT II half-lives of control and patient fibroblasts
Cultured fibroblasts were washed with PBS and incubated for 48 h in serum- and methionine-
free medium 30 min, then followed by pulse chase labeling with [35S]-methionine (specific ac-
tivity 1,000 Ci/mM) for 2 h. After pulse labeling, the fibroblasts were again washed with PBS
and chased for 0, 6, 12, and 18 h. At each chase interval, the fibroblasts were lysed and immu-
noprecipitated with anti-CPT II antibody coupled to Protein G-Sepharose 4B. Then the immu-
noprecipitates were separated by SDS-PAGE and the dried gels were analyzed
autoradiographically [20, 21].
Mitochondrial fatty acid β-oxidation and ATP generation
The β-oxidation of mitochondrial fatty acids was analyzed as previously described by Saudu-
bray et al. [20]. Control and patient fibroblasts were cultured at 37°C or 41°C in plastic center
containing a filter paper, then continue cultured for an additional 2 h. At the end of the incuba-
tion, the reaction was stopped by the addition of perchloric acid, and the radioactive CO2 re-
leased from the fibroblasts was collected for 1 h at room temperature by injecting NaOH onto
the filter paper under slow shaking. The filter papers were retrieved and the amount of 14CO2
radioactivity was counted using liquid scintillation counting in ACS II in a Beckman LS 6500
multi-purpose scintillation counter [20].
Fibroblasts were washed twice with PBS and cellular ATP was extracted with 1% trichloro-
acetic acid, then the ATP production concentration was measured. The extracts were centri-
fuged and immediately diluted with 1 M Tris-acetate buffer. The total ATP generation in the
extracts was measured by an ATP assay system bioluminescence detection kit according to the
manufacturer’s instructions.
Statistical analysis
The data were statistical analyzed using SPSS 15.0 for windows. The Student’s t-test was used
for comparison between the groups. P<0.05 was considered statistically significant. All data
were expressed as mean ± SD.
Results
CPT2 polymorphisms in CPT II deficiency patients
Genotype analyses of CPT2 in patients suffering from CPT II deficiency identified three poly-
morphisms associated with amino acid substitutions: [c.1102 G>A (p.V368I)] (heterozygous),
[c.1102 G>A (p.V368I)] (homozygous), and [c.1055 T>G (p.F352C)] (heterozygous) +
[c.1102 G>A (p.V368I)] (homozygous). These variations matched the mutations previously
reported in late-onset muscular, infantile/juvenile hepatic, and severe neonatal phenotypes of
CPT II deficiency [24–30]. Mutations [c.1055 T>G (p.F352C)] (heterozygous) + [c.1102 G>A
(p.V368I)] (homozygous) are located near the acylcarnitine binding residues [26], and tran-
sient serum acylcarnitine ratios [(C16:0 + C18:1)/C2] of>0.09 were previously observed during
high fever. These variations were found not only in disease-causing mutations defined as path-
ogenic but also found in polymorphisms of CPT2 gene associated with inherited CPT II defi-
ciency. The three polymorphisms found in CPT2 gene and in the studied patients [c.1102
G>A (p.V368I)] (heterozygous), [c.1102 G>A (p.V368I)] (homozygous), and [c.1055 T>G
(p.F352C)] (heterozygous) + [c.1102 G>A (p.V368I)] (homozygous) matched the mutations
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previously reported in late-onset muscular, infantile/juvenile hepatic, and severe neonatal phe-
notypes of CPT II deficiency.
Enzymatic properties and thermal instability of CPT II variants
We next examined the CPT II activity and kinetic properties of fibroblast lysates. The CPT II ac-
tivity of control fibroblasts was 0.28 ± 0.05 nmol/min/mg protein (n = 5), that of p.V368I (ho-
mozygous) was 0.27 ± 0.05 nmol/min/mg protein (n = 5), p.F352C (homozygous) was 0.18 ±
0.05 nmol/min/mg protein (n = 5), and p.F352C + p.V368I was 0.15 ± 0.05 nmol/min/mg pro-
tein (n = 5) (S2 Table). These results are similar to those reported in a previous study [20–23].
We previously reported that CPT II deficiency is a thermolabile phenotype of compound
hetero-/homozygous variants [20–23], so we next evaluated the temperature sensitivity of CPT
II variants. Fibroblast lysates were pre-incubated at 41°C or 30°C for 0–2 h, and then CPT II ac-
tivities were measured at 30°C following the addition of L-carnitine and palmitoyl-CoA sub-
strates (Fig. 1). Of the three variants, p.F352C + p.V368I was the most unstable, with
significantly reduced enzyme activities during incubation at 41°C; under the same conditions,
the activities of control fibroblasts and those from variants p.V368I (heterozygous) and p.
V368I (homozygous) remained low and were also markedly reduced.
CPT II expression and dominant—negative effect
Previous studies of enzyme activity in fibroblasts of CPT II-deficient patients revealed similar
CPT II activities for homozygous and compound heterozygous CPT2mutations [19], suggesting
that mutant CPT2 exert a dominant negative effect on the CPT II protein [31]. We therefore fur-
ther examined the Vmax and Km values for L-carnitine of CPT II variant fibroblasts. Vmax and
Km values of p.V368I (homozygous) were similar to those of p.F352C (heterozygous) + p.V368I
(homozygous) (Fig. 2B). These data confirm an effect of homozygous and heterozygous CPT2
mutations on the enzymatic properties of the homotetrameric protein compared with those of
control CPT II.
Fig 1. CPT II activities and thermal instability in CPT II-deficient fibroblasts. Fibroblast lysates were
preincubated at 37°C or 41°C. Enzymatic reactions commenced by the addition of substrates at 37°C. Data
are the means of five separate experiments. The average of three independent experiments is shown ± SEM
(*P<0.05).
doi:10.1371/journal.pone.0119936.g001
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To evaluate the stability of these variant CPT IIs, we analyzed CPT II mRNA and protein
expression in control and patient fibroblasts. CPT II protein expression levels of p.F352C + p.
V368I were significantly lower than p.V368I and p.V368I compared the CPT II protein expres-
sion levels of p.F352C +p.V368I with p.V368I and p.V368I according to Western Blotting
(Fig. 2A, 2C), although mRNA levels, as measured by real-time PCR, were comparable
(Fig. 2D). This indicates that the functional disorder of CPT II deficiency does not compromise
the synthesis of polypeptides, but instead appears to impair the intracellular stability of folded
CPT II proteins.
Short half-lives of CPT II variants
To examine the intracellular stability of CPT II variants, we metabolically labeled control and
patient fibroblasts with L-[35S] methionine and measured their half-lives using a pulse-chase
protocol (Fig. 3, left). No differences were detected in the concentrations of newly synthesized
and labeled CPT II proteins between the immunoprecipitates of control and patient fibroblasts,
suggesting that the synthesis of control and patient CPT IIs was similarly efficient. Time course
experiments showed that control CPT IIs had the longest half-life (T1/2 ~ 18 h), similar to our
Fig 2. CPT II expression and the dominant—negative effect ofCPT II variants on substrate-dependent
kinetics. (A) CPT II expression was analyzed byWestern Blotting with an anti-CPT II antibody. (B) Dominant—
negative effect ofCPT II variants was analyzed by substrate-dependent kinetics. (C) Relative protein expression
of control and variant CPT II. (D) Real-time PCR analysis of control and variantCPT II expression. Lane 1,
control fibroblasts; lane 2, V368I (heterozygous); lane 3, V368I (homozygous); lane 4, F352C (heterozygous) +
V368I (homozygous). CPT II protein was expressed relative to β-actin. Vmax and Km values were obtained from
kinetic analysis (1/V versus 1/[S] plots) by varying the concentrations of L-[methyl-3H] carnitine between 0–300
μMat a fixed 50 μMpalmitoyl-CoA concentration. (●) control, (▲) V368I (Homo), (◆) F352C (Hetero) + V368I
(Homo). Data are means of three separate experiments. The average of three independent experiments is
shown ± SEM (*P<0.05)
doi:10.1371/journal.pone.0119936.g002
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previous data, while the half-life of p.V368I (homozygous) was shorter at T1/2 ~ 10 h, and that
of p.F352C (heterozygous) + p.V368I (homozygous) was significantly shorter, at T1/2 ~ 4 h
(Fig. 3, right).
Reduction of mitochondrial membrane potential
We assessed the mitochondrial membrane potential (ΔCm) using the cationic lipophilic probe
JC-1. Normal mitochondria with a high ΔCm appear red following aggregation of JC-1, which
emits red fluorescence at ~590 nm. Following mitochondrial depolarization with a low ΔCm,
the JC-1 dye remains in its monomeric form, thereby emitting relatively more green (~525
nm) fluorescence [32]. We observed an increase of green fluorescence and a reduction of red
fluorescence in the mitochondria of fibroblasts from patients with p.V368I (homozygous) and
p.F352C (heterozygous) + p.V368I (homozygous) variants compared with mitochondria from
control fibroblasts at both 37°C (Fig. 4A, B, C) and 41°C (Fig. 4D, E, F). Mitochondrial depolar-
ization is a marker of mitochondrial dysfunction and precedes ATP depletion, so the data indi-
cate a relatively low ΔCm of patient fibroblasts at 37°C and an enhanced decrease in ΔCm
under heat-stress conditions at 41°C.
Cell apoptosis of CPT II variants
To assay cell apoptosis induced by CPT II deficiency, the percentage of apoptotic fibroblasts
was measured in control and patient fibroblasts. Flow cytometry analysis revealed a significant
increase in apoptosis of cultured patient fibroblasts from p.V368I (homozygous) and p.F352C
(heterozygous) + p.V368I (homozygous) variants compared with control fibroblasts (Fig. 5A).
LDH is a stable cytoplasmic enzyme that catalyzes the interconversion of lactate and pyru-
vate. It is ubiquitously expressed in all cells and is rapidly released into the supernatant upon
the plasma membrane damage. Therefore, measurement of its activity can be used to quantify
plasma membrane damage. We observed a significant increase, seen as a percentage of LDH
Fig 3. Pulse-chase (left) and half-lives (right) of control and variant CPT II in fibroblasts. Cultured fibroblasts were pulse-labeled with L-[35S] methionine
for 2 h and chased for 0, 6, 12, and 18 h. CPT II from fibroblast lysates was immunoprecipitated with anti-CPT II antibodies, then subjected to SDS-PAGE
followed by autoradiography. (●) control, (&) V368I (homozygous), (▲) F352C (heterozygous) + V368I (homozygous). The average of three independent
experiments is shown ± SEM.
doi:10.1371/journal.pone.0119936.g003
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release, in damage to cultured patient fibroblasts p.V368I (homozygous) and p.F352C (hetero-
zygous) + p.V368I (homozygous) (Fig. 5B).
To further evaluate the apoptotic effect in CPT II variants, the expression of apoptosis factors
was analyzed by immunoblotting. Caspases are responsible for the deliberate of cells into apopto-
tic bodies during cell apoptosis. Caspases 3 and caspases 8 are situated at important junctions in
apoptosis pathways, and activate disassembly in response to agents or insults that trigger the cy-
tochrome c release frommitochondria. Caspase 3 amplifies caspase 8 initiation signals into a
commitment to disassembly, while caspase 8 activates caspase 3 by proteolytic cleavage and
cleaves vital cellular proteins. In the present study, Western Blotting showed that apoptotic factor
was significantly released (Fig. 5C). Moreover, caspase-3, caspase-8, cytochrome c, and Bid,
which induces apoptosis and allows the release of cytochrome c, were all expressed at higher lev-
els in fibroblasts from p.V368I (homozygous) and p.F352C (heterozygous) + p.V368I (homozy-
gous) variants compared with control fibroblasts.
Correlation between CPT II activity and ATP generation
To further clarify the metabolic disorder resulting from CPT II deficiency, the effects of ther-
mal instability, CPT II enzymatic activities (S2 Table), fatty acid oxidation flux, and cellular
ATP production were analyzed at 37°C and 41°C in patient fibroblasts p.V368I (homozygous),
p.F352C (heterozygous) + p.V368I (homozygous) and control fibroblasts (Fig. 6). CPT II activ-
ities, ATP production, fatty acid oxidation and of fibroblasts from patients with the p.V368I
(homozygous) variant were decreased to 85–95% of control values at 41°C and to 85–95% of
control fibroblasts at 37°C. However, fibroblasts from patients with the p.F352C (heterozy-
gous) + p.V368I (homozygous) variant exhibited significantly decreased CPT II activity to
40–60%, and ATP production and fatty acid oxidation to 50–70% of control values at 41°C,
and to control fibroblasts at 37°C, with further inactivation of CPT II activity at increasing tem-
peratures. The effect of the attenuated CPT II activity on cellular production of ATP was slight-
ly less than that on fatty acid oxidation.
Fig 4. Reduction of mitochondrial membrane potential of control and variant CPT IIs in cultured fibroblasts. Control (A, D), V368I (homozygous)
(B, E), and F352C (heterozygous) + V368I (homozygous) (C, F) fibroblasts were cultured at 37°C and 41°C. Mitochondrial depolarization was monitored by
15 min treatment with 10 μM of JC-1 in the dark and visualized under a fluorescence microscope. Scale bars, 100 μm.
doi:10.1371/journal.pone.0119936.g004
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Discussion
Carnitine palmitoyltransferase II deficiency is the most common inborn errors of long-chain
fatty acid oxidation and ATP generation, involving an increase in the concentrations of acyl-
carnitine in the serum [31–34]. In our previous data, we observed a transient and rapid increase
of acylcarnitine ratio [(C16:0 + C18:1)/C2] to>0.09 in the serum during febrile convulsions that
in the patients presenting with high risk influenza-associated encephalopathy, in the absence of
previous episodes [24]. Because of the CPT II inactivation the rise in serum acylcarnitine prob-
ably caused by the presence of some disease causing mutations. However, these are not identi-
cal to the CPT2mutations observed in CPT II deficiency, which has a more severe phenotype.
Although a large proportion of CPT II deficiency patients exhibit phenotype of compound
hetero/homozygous variations [26–30], the molecular mechanism of how the CPT II deficiency
induces energy crisis has yet to be clarified. The genotype-phenotype correlation analysis of
CPT2missense mutations has enabled the myopathic form of CPT II deficiency to be associat-
ed with “mild”mutations, while the null mutations resulting to truncation of mRNA or protein
degradation are associated with the lethal neonatal forms [18, 30, 35–38]. Many disease causing
mutations from inherited disorders effect on impair protein folding or reduce protein stability
despite almost normal protein folding. In the present study, we analyzed three types of CPT II
variations: p.V368I (heterozygous), p.V368I (homozygous), and p.F352C (heterozygous) + p.
V368I (homozygous). Our data indicated that the fibroblasts of patients with these variants ex-
hibited decreased enzyme activities, cellular β-oxidation, ATP generation, and ΔCm, with in-
creased Km values for L-carnitine, thermal instability, short half-lives, and cellular apoptosis. p.
F352C (heterozygous) + p.V368I (homozygous) fibroblasts showed a particularly prominent
Fig 5. Cell apoptosis analysis ofCPT II variants in fibroblasts. (A) Apoptotic fibroblasts were measured
by flow cytometry. Fibroblasts incubated with DMSOwere used as a control. (B) LDH assay of control and
CPT II variants in fibroblasts. (C) Apoptotic factor release was analyzed byWestern Blotting with antibodies
against caspase-3, caspase-8, cytochrome c, and Bid for control and variant CPT IIs in control and CPT II-
deficient fibroblasts. CPT II proteins are expressed relative to β-actin. Data are means of three separate
experiments. The average of three independent experiments is shown ± SEM (*P<0.05).
doi:10.1371/journal.pone.0119936.g005
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decrease in enzyme activity, β-oxidation, ATP generation, ΔCm, and lowered thermal stability,
especially at 41°C and despite being located far from the acylcarnitine binding sites in the case
of the p.F352C variant. The p.V368I variant is located near the acylcarnitine binding sites,
though this appeared to have little effect on enzyme properties. Our work confirmed that CPT
II variations have a dominant-negative effect on CPT II protein as shown previously in correla-
tion researches between clinical metabolic and genotype data [18–26].
CPT2mutations have been reported to cause several metabolic disorders including general
muscle damage, temperature changes, infections, disturbances of Na+/K+ ATPases, neuroleptic
syndrome, excessive use of muscular force, and conditions related to lipid metabolism increases.
Patients with these disorders require more energy than that is provided by glycolytic system, so
rely on that provided by fatty acid oxidation pathway. Because CPT II is not a rate limiting en-
zyme for fatty acid β-oxidation and ATP product, the activity decrease does not correlate linear-
ly with the fatty acid β-oxidation or ATP generation decrease. However, the thermolabile
phenotype of CPT2 polymorphism p.F352C demonstrates reduced CPT II enzyme activity.
Our current study characterized the enzymatic properties of CPT II variants found in pa-
tients with CPT II deficiency and defined the correlation between genotype and metabolism of
β-oxidation, ATP production, and ΔCm. The p.F352C (heterozygous) + p.V368I (homozygous)
variant is associated with an energy crisis, especially at high temperature, and as such is sus-
pected to be a risk factor for acute encephalopathy. The sudden-onset brain edema with clinical
manifestation in patients supports the ATP threshold hypothesis in the etiology of this kind
edema. The significantly reduced ATP levels and markedly reduced ΔCm observed in the fibro-
blasts of this variant at 41°C suggests that such thermolabile compound variants of CPT II re-
duced fuel utilization in brain endothelial cells may be a cause of this kind acute brain edema
during fever in the affected patients [39–41]. Moreover, the short half-lives and thermal
Fig 6. Correlation between CPT II activity and β-oxidation/ATP production at 41°C and 37°C in CPT II-
deficient fibroblasts. (●) control, (&) V368I (homozygous), (4) F352C (heterozygous) + V368I
(homozygous). CPT II activity, β-oxidation, and ATP production are expressed as % of control values of
control fibroblasts at 37°C. Data areand means of five separate experiments: 0.53 nmol/min/mg protein of
CPT II activity; 14.5 nmol of released CO2/h/10
6 cells; 8.12 nmol of ATP/106 cells. The average of three
independent experiments is shown ± SEM.
doi:10.1371/journal.pone.0119936.g006
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instability of these CPT II variants may play an important role in decreasing ATP levels below
the phenotypic threshold. These acquired short half lives, cell apoptosis, impaired mitochondrial
fuel utilization, together with the serum acylcarnitine level rise that occurs during high fever,
could be hypothesized as the main cause of energy crisis and multiple organ failure (Fig. 7).
Fibrates are hypolipidemic drugs that increase lipoprotein levels by up-regulating the
mRNA expression of metabolism genes via the steroid—thyroid PPARa transcription factor in-
teractions. Bezafibrate has been reported to increase CPT2mRNA expression and to normalize
enzyme activity in cultured CPT II-deficient fibroblasts. CPT II-deficient patients administered
bezafibrate also showed a normalization of fatty acid oxidation levels, and increased CPT II
mRNA and protein levels [42–44]. Additional studies are currently underway to further exam-
ine the effects of fibrates on CPT II-deficient patients.
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